长期口服依托泊甙胶囊治疗肺癌和恶性淋巴瘤

Chronic daily adminisitration of oral etoposide capsule in lung cancer and malignant lymphoma

用依托泊甙（Ｅｔｏ）胶囊口服用药联合化疗方案治疗肺癌和恶性淋巴瘤１７人，并以１０例静脉滴注Ｅｔｏ作对照。结果：口服Ｅｔｏ胶囊组总有效率为８８％，对照组为６０％。肺癌口服Ｅｔｏ胶囊治疗组有效率（８９％）明显高于对照组（４３％），Ｐ＜０．０５。２组毒副作用相似。提示：口服Ｅｔｏ胶囊联合化疗对肺癌和恶性淋巴瘤的疗效不低于静脉用药组，值得进一步研究。

Seventeen patients with lung cancer and malignant lymphoma were treated with combination chemotherapy including oral etoposide (Eto). The efficacy of oral Eto was compared with that of iv in 10 patients in same chemotherapy regimen. The overall response rates were 88%(oral) and 60%(iv), respectively. In lung cancer patients, the response rate(89%) is oral treatment was higher than that(43%) in iv, P< 0.05. Toxic effects induced by Eto were not different between the two regimens. Our results showed that the curative effect in oral treatment was close to that in iv. As the patient number is not large enough, the results are preliminary and necessary to study further.